Krishna Yeshwant
CIK 1585001 · last filed 2026-06-11
Krishna Yeshwant is a corporate insider who has filed 24 SEC Form 4 insider transactions across 4 companies since 2013. The most recent filing, for PBLS, was dated Jun 11, 2026. Across all open-market trades the lifetime net is +$3.3M, making them a net buyer over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
4
24
$3.33M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PBLS | Director | — | — | — | $0 | 1 | 2026-06-11 |
| Verve Therapeutics, Inc. (VERV) Delisted | Director | 0 | $11.13 | $0 | $10.58M | 10 | 2025-07-28 |
| EQRx, Inc. (EQRXW) Delisted | Director | — | $0.05 | — | $0 | 2 | 2023-11-09 |
| Foundation Medicine, Inc. (FMI) Delisted | Director | 120,267 | — | — | -$7.25M | 10 | 2017-08-10 |
Recent Filings
24 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-11 | PBLS | Grant (A) | — | $0 | EDGAR |
| 2025-07-28 | Verve Therapeutics, Inc. (VERV) Delisted | Mixed | −12,168,489 | $0 | EDGAR |
| 2025-06-06 | Verve Therapeutics, Inc. (VERV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-28 | Verve Therapeutics, Inc. (VERV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-05 | Verve Therapeutics, Inc. (VERV) Delisted | Buy (P) | +1,800,000 | $18.00M | EDGAR |
| 2023-11-09 | EQRx, Inc. (EQRXW) Delisted | Disp (D) | — | $0 | EDGAR |
| 2023-06-20 | Verve Therapeutics, Inc. (VERV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-11-08 | Verve Therapeutics, Inc. (VERV) Delisted | Mixed | −97,166 | -$1.51M | EDGAR |
| 2022-11-04 | Verve Therapeutics, Inc. (VERV) Delisted | Mixed | −156,440 | -$2.66M | EDGAR |
| 2022-11-02 | Verve Therapeutics, Inc. (VERV) Delisted | Mixed | −171,319 | -$3.25M | EDGAR |